Effects of Fenofibrate on Metabolic and Reproductive Parameters in Polycystic Ovary Syndrome
Status:
Terminated
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
This is a prospective randomized, double-blind placebo-controlled trial of 6 months' duration
evaluating the effect of fenofibrate (200 mg/day) in females with polycystic ovary syndrome
and mild hypertriglyceridemia. The investigators primary objective will be to determine
whether fenofibrate will reduce hepatic adiposity as measured using MRI, and our secondary
outcomes will be to delineate the impact of fenofibrate on biochemical or clinical parameters
for insulin resistance, cardiovascular disease, and reproductive status.